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Summary
Background Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly in the UK because of 
a single strain (the so-called original UK strain) belonging to the hypervirulent sequence type-11 clonal complex (cc11), 
with a variant outbreak strain (the so-called 2013 strain) emerging in 2013. Subsequently, the Netherlands has had an 
increase in the incidence of meningococcal serogroup W disease. We assessed the temporal and phylogenetic associations 
between the serogroup W outbreaks in the Netherlands and England, and the historical serogroup C outbreaks in both 
countries.
Methods For this observational cohort study, we used national surveillance data for meningococcal serogroup W and 
serogroup C disease in the Netherlands and England for the epidemiological years (July to June) 1992–93 to 2015–16. 
We also did whole genome sequencing and core genome multilocus sequence typing (1546 loci) on serogroup W 
disease isolates from both countries for surveillance years 2008–09 to 2015–16. We used Poisson regression to 
compare the annual relative increase in the incidence of serogroup W and serogroup C between both countries.
Findings In the Netherlands, the incidence of meningococcal serogroup W disease increased substantially in 
2015–16 compared with 2014–15, with an incidence rate ratio of 5·2 (95% CI 2·0−13·5) and 11% case fatality. In 
England, the incidence increased substantially in 2012–13 compared with 2011–12, with an incidence rate ratio of 
1·8 (1·2−2·8). The relative increase in the Netherlands from 2014–15 to 2015–16 was 418% (95% CI 99−1248), 
which was significantly higher than the annual relative increase of 79% (61−99) per year in England from 
2011–12 to 2014–15 (p=0·03). Cases due to meningococcal serogroup W cc11 (MenW:cc11) emerged in 2012–13 in 
the Netherlands. Of 29 MenW:cc11 cases found up to 2015–16, 26 (90%) were caused by the 2013 strain. For both the 
current serogroup W outbreak and the historical serogroup C outbreak, the increase in incidence started several 
years later in the Netherlands than in England, the rate of increase was higher in the Netherlands, and age 
distributions were similar in both countries.
Interpretation Given the historical similarities of meningococcal serogroup W with meningococcal serogroup C 
emergence, the rapid expansion of the MenW:cc11 2013 strain in the Netherlands, its high case fatality, and the 
availability of a safe and effective vaccine, urgent consideration is needed for public health interventions in the 
Netherlands and other affected countries to prevent further serogroup W cases and deaths.
Funding National Institute for Public Health and the Environment (Netherlands), Academic Medical Center 
(Netherlands), and Public Health England.
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Introduction
Meningococcal disease is caused by the Gram-negative 
bacterium Neisseria meningitidis and can cause severe 
disease including septicaemia and meningitis. Because 
meningococcal disease progresses rapidly, often presenting 
initially with non-specific symptoms, it is not always 
recognised in time, which contributes to the high case 
fatality and devastating long-term consequences for 
survivors.1 Lifelong severe sequelae occur in 6% of 
survivors of meningococcal disease, and include deafness, 
limb amputation, and brain damage.1 In a study from the 
Netherlands, 32% of children who survived bacterial 
meningitis (caused by various pathogens including 
N meningitidis) had cognitive limitations, behavioural 
limitations, or both.2 Different meningococcal serogroups 
can be discerned on the basis of differences in the 
polysaccharide capsule, of which serogroups A, B, C, W, Y, 
and X cause most meningococcal disease worldwide.3
In England and Wales, the occurrence of invasive 
meningococcal disease was fairly stable in the early 1990s, 
with around 1200 laboratory-confirmed cases and an 
incidence of approximately 2·3 cases per 100 000 population 
reported each year up to 1994–95.4 However, from 1995–96, 
the incidence of laboratory-confirmed disease increased, 
peaking at 5·4 cases per 100 000 population in 1998–99. 
This increase was mostly attributable to an increase in 
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meningococcal serogroup C disease; between 1994–95 and 
1995–96, the number of cases of serogroup C disease more 
than doubled and the proportion of meningococcal disease 
cases caused by serogroup C infection increased from 
25% to 36%.4 This increase led to accelerated clinical trial 
programmes for meningo coccal conjugate vaccines in the 
UK, resulting in the introduction of a routine serogroup C 
meningococcal (MenC) vaccination programme for infants 
and a catch-up campaign for all other children up to the 
age of 18 years from November, 1999.
The Netherlands also had an increase in the incidence 
of meningococcal serogroup C disease, from 0·5 cases 
per 100 000 population per year during 1993−99 to 0·7 per 
100 000 population in 2000 and 1·7 per 100 000 population 
in 2001.5 Consequently, a serogroup C conjugate vaccine 
was introduced into the national immunisation pro-
gramme in September, 2002, for 14-month-old children, 
and a catch-up campaign was implemented for children 
aged 14 months to 18 years. In both the UK and 
the Netherlands, the vaccination programmes led to rapid 
and sustained control of serogroup C disease.6,7
Currently, the UK has an ongoing national outbreak of 
meningococcal serogroup W disease, with the number of 
cases increasing from 19 in 2008–09 to 176 in 2014–15.8,9 
Most patients with serogroup W disease were previously 
healthy (81%) and the case fatality rate of 12% is 
significantly higher than that reported for serogroup B 
disease (<5%).9 Because of the continuing rapid increase 
in serogroup W disease, the UK replaced the adolescent 
MenC conjugate vaccine for 13−14 year olds and new 
university entrants with the quadrivalent conjugate 
meningococcal vaccination (MenACWY) in the autumn 
of 2015.8,10,11 Additionally, catch-up campaigns are being 
implemented to offer the MenACWY vaccine to all 
13−18 year olds during 2015 to 2017.
The increase in meningococcal serogroup W disease 
in the UK was initially due to the rapid expansion of a 
single strain of sequence type (ST)-11 clonal complex 
(cc11).9 Previous genomic analyses of geotemporally 
diverse meningococcal cc11 strains of various 
serogroups showed that most meningococcal serogroup 
W cc11 (MenW:cc11) isolates belonged to cc11 lineage 
11.1, following what is believed to be a single capsular 
switching event that occurred prior to 1970.12,13 There are 
two main divergent serogroup W-associated sublineages 
of lineage 11.1: the Hajj strain sublineage and the South 
American strain sublineage.12 The Hajj strain sublineage 
includes the Hajj strains that caused local and national 
outbreaks in different parts of the world during the 
early 2000s. The South American strain sublineage 
includes the South American strain that emerged in 
2003 in southern Brazil, then spread to Argentina and 
Chile. A descendent of the South American strain, the 
so-called original UK strain, emerged in the UK in 2009. 
Genomic analyses revealed the expansion of a further 
descendent strain in the UK, the 2013 strain (so called to 
Research in context
Evidence before this study
On Feb 14, 2017, we searched MEDLINE, Embase, SciSearch, 
and BIOSIS Previews for reports of meningococcal serogroup W 
disease in Europe, published since Jan 1, 2010, with no 
language restrictions. We did this literature search using terms 
for meningococcal serogroup W disease in combination with 
search terms for European countries. We identified 185 reports, 
including 19 with information on the incidence of 
meningococcal serogroup W disease in a European country 
since 2010. Of these 19 reports, ten were from the UK, six were 
from other European countries (Austria, Spain, and two 
publications each from the Czech Republic and Poland), and 
three included data from multiple countries, including Sweden. 
The reports from the UK showed that since 2009, the 
meningococcal serogroup W cc11 (MenW:cc11) 
South American strain sublineage has diversified with the 
emergence of a related strain, which expanded to cause an 
outbreak of serogroup W disease that is still ongoing in the UK. 
This outbreak has been accompanied by the rapid expansion of 
an emergent substrain in the UK since 2013. In response to the 
serogroup W outbreaks, quadrivalent conjugate meningococcal 
vaccination (MenACWY) programmes were implemented in 
the UK. Also in Europe, increasing incidence of serogroup W 
disease has been reported in Spain and Sweden. Reports from 
Austria and Poland did not include data for years since 2012. 
The increase in serogroup W disease in Spain and Sweden was 
attributed to the emergence of a strain with a similar typing 
profile as the MenW:cc11 South American strain and other 
MenW:cc11 sublineages (W:P1.5,2:ST-11).
Added value of this study
Our results show the emergence of the MenW:cc11 outbreak 
strain in the Netherlands, particularly the variant that emerged in 
the UK in 2013. The increase in incidence of meningococcal 
serogroup W disease in the Netherlands started 3 years after the 
increase in serogroup W incidence in England, and the rate of 
increase was higher in the Netherlands. This pattern resembles 
the historical outbreak of serogroup C disease around 2000, 
in which the increase in the Netherlands also started several years 
after the increase in England and the rate of increase was also 
higher in the Netherlands. Additionally, the age distributions of 
the serogroup W cases belonging to the MenW:cc11 outbreak 
strain were similar between the Netherlands and England.
Implications of all the available evidence
Given the rapid expansion of the MenW:cc11 strain causing 
meningococcal disease in the UK, the Netherlands, and several 
other European countries, close monitoring is needed in all 
European countries, along with early considerations for public 
health interventions, including vaccination.
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reflect its year of emergence). Genetic differences 
between the original UK strain and the 2013 strain 
included four point mutations and three putative 
recombination events.14 In the Netherlands, serogroup W 
disease was rare up to 2014, but its incidence increased 
in 2015 and 2016.15
The aim of our study was to describe the current 
outbreak of meningococcal serogroup W disease in the 
Netherlands and to compare its epidemiology and 
phylogeny with the serogroup W outbreak in England. To 
provide context for this comparison, we also analysed 
historical data from the national serogroup C outbreaks 
(also due to cc11) that occurred around 1998−2001 in both 
countries. Although serogroup B disease is a major 
contributor to meningococcal disease in the Netherlands 
and England, we did not include it in this study because 
serogroup B disease has been declining for the past 
20 years in both countries and is rarely associated with 
cc11. The aim of the analysis was to gain insight into how 
the Dutch serogroup W outbreak is evolving, to inform 
vaccine policy in the Netherlands and beyond.
Methods
Surveillance data
In this observational cohort study, we used data from 
the Netherlands Reference Laboratory for Bacterial 
Meningitis (NRLBM), which receives N meningitidis 
isolates from blood and cerebrospinal fluid (CSF) from 
all micro biological laboratories in the Netherlands on a 
voluntary basis. Serogroup is assessed by Ouchterlony 
gel diffusion.16 From 1985 to 2005, serosubtyping based 
on differences in outer membrane proteins PorB and 
PorA was done.17 Fine typing has been based on 
sequencing of PorA since 2001 and sequencing of FetA 
protein since 2005.18 In addition to N meningitidis isolates, 
laboratories can also submit PCR-positive samples from 
invasive sites to the NRLBM; the capsular group is then 
determined by real-time (rt) PCR with group-specific 
probes. Briefly, serogroup W was detected in CSF and 
blood by use of rtPCR with a Lightcycler 480 (Roche 
LifeScience, Mannheim, Germany). Primers were 
NMFW135 (CAGAAAGTGAGGGATTTCCATA) and 
NMRW135 (CACAACCATTTTCATTATAGTTACTGT), 
and the probe was NMPW135 (6FAM-
TGGAAGGCATGGTGTATGATATTC-BHQ1). Whole-
genome sequencing19 has been done on all serogroup W 
isolates received from 2008–09 to 2015–16. Meningococcal 
disease has been a notifiable disease in the Netherlands 
since 1905. Since 2003, data from the laboratory 
surveillance and the notification system have been linked 
through date of birth, sex, postal code, and (approximate) 
date of diagnosis. If a case is missing in one of the 
sources, we actively request that the case is officially 
notified or that the material is sent to the NRLBM, as 
appropriate. Serogrouping is done by the NRLBM and 
not by local laboratories. Therefore, if material has not 
been sent to the NRLBM, the serogroup is not known 
and we did not include these cases in this analysis of 
serogroup W and serogroup C. The percentage of cases 
notified for which material has been sent to the NRLBM 
is 90−95%.
Public Health England (PHE) routinely conducts 
national surveillance of meningococcal disease using a 
combination of clinical and laboratory reporting schemes.4 
PHE’s Meningococcal Reference Unit (MRU) establishes 
the serogroup, serotype, and serosubtype of all invasive 
N meningitidis isolates and offers a free, national PCR 
service for patients with suspected meningococcal disease 
to confirm the diagnosis and establish the capsular group. 
Ascertainment of cases on the basis of laboratory 
confirmation by the PHE MRU is very high.20,21 Since 
July, 2010, all invasive isolates received by the MRU have 
Figure 1: Incidence of invasive meningococcal disease in the Netherlands and England
Incidence of meningococcal serogroup W and serogroup C disease by epidemiological year (July to June). Arrows 
show the start of implementation of quadrivalent conjugate meningococcal vaccine (MenACWY) in the UK in 
2015, and meningococcal serogroup C vaccination in the UK in 1999 and the Netherlands in 2002.
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Figure 2: Genomic analysis of the MenW:cc11 South American strain sublineage
Neighbour-net phylogenetic network of all available genomes of MenW:cc11 South American strain sublineage isolates from England and the Netherlands, 2009–10 
to 2015–16. Colours represent the epidemiological year the sample was acquired. The insert shows the position of individual strains within the South American strain 
sublineage. cc11=sequence type-11 clonal complex.
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undergone whole genome sequencing. Genomic data for 
invasive MenW:cc11 isolates from 2008–09 were available 
as part of a specific study.12
Epidemiological analyses
We compared the incidence and age distribution of 
meningococcal serogroup W and serogroup C disease in 
the Netherlands and England during the epidemiological 
years (July to June) 1998–99 to 2015–16 for serogroup W 
and 1992–93 to 2003–04 for serogroup C. We used Poisson 
regression to estimate the annual relative increase in 
incidence during the outbreaks of serogroup C and 
serogroup W disease in the Netherlands and England. We 
estimated the annual relative increase from the start of the 
serogroup C or serogroup W outbreak (ie, the first year in 
which the incidence was significantly higher than that of 
the previous year) until the year before vaccination was 
introduced. We tested whether the annual relative increase 
differed between the Netherlands and England by 
including an interaction term between time and country in 
the model. We did these analyses using SPSS version 24.
Genomic analyses
We obtained genome sequence data for all invasive 
meningococcal serogroup W isolates collected in 
England from 2010–11 to 2015–16 (n=501) from the 
Meningitis Research Foundation Meningococcus 
Genome Library.22 Additionally, genome sequence data 
for five invasive South American strain sublineage 
MenW:cc11 isolates collected in England from 2008–09 
to 2009–10 were available from an earlier study.12 For the 
Netherlands, 53 (98%) of 54 serogroup W isolates from 
2008–09 to 2015–16 underwent whole genome 
sequencing. We extracted multilocus sequence typing 
(MLST) data from the PubMLST Neisseria database 
using the export dataset analysis tool.23
We compared genomes using the PubMLST genome 
comparator tool.24 We established respective sublineages 
for MenW:cc11 genomes submitted to the PubMLST 
Neisseria database subsequent to previous analyses on 
Jan 21, 2016.14 We did this by comparing genomes to a 
representative panel of isolates spanning the known 
diversity of cc1114 in terms of 1546 core genes.9 With the 
exception of nine genomes consisting of more than 
500 contigs, we then made core genome comparisons for 
all South American strain sublineage genomes (n=689) 
on the PubMLST Neisseria database (accessed Nov 8, 
2016) and a distant cc11 reference genome (lineage 11.1; 
ID 30060).9 We visualised the resulting distance matrices 
with SplitsTree4 version 4.13.1.25
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
From 1998–99 to 2015–16, 1182 cases of meningococcal 
serogroup W disease were reported in England and 
126 cases were reported in the Netherlands. Figure 1 
shows the incidence of serogroup W disease in the 
Netherlands and England by epidemiological year from 
1998–99 to 2015–16. The increase in serogroup W disease 
incidence in 1999–2000 and 2000–01 in both countries 
was due to an outbreak associated with the Hajj to 
Saudi Arabia.26 In England, the incidence of serogroup W 
disease increased significantly in 2012–13 compared 
with the previous year, from 0·06 cases per 100 000 in 
2011–12 to 0·10 cases per 100 000 in 2012–13 (incidence 
rate ratio 1·8, 95% CI 1·2−2·8). In the Netherlands, the 
average incidence of serogroup W disease from 2002–03 
to 2014–15 was 0·03 cases per 100 000 population per 
year, but in 2015–16 increased significantly to 0·15 cases 
per 100 000 population (incidence rate ratio 5·2 
[2·0−13·5] compared with 2014–15). The relative increase 
in the Netherlands from 2014–15 to 2015–16 was 418% 
(95% CI 99−1248), which was significantly higher than 
the relative increase of 79% (61−99) per year in England 
from 2011–12 to 2014–15 (p=0·03). In 2015–16, the 
incidence of serogroup W disease in the Netherlands 
(0·15 cases per 100 000 population per year) was similar 
to that in England in 2013–14 (0·18 cases per 
100 000 population per year). In the third and fourth 
quarter of 2016 (July to December) and the first quarter 
of 2017 (January to March), 53 cases of serogroup W 
disease were confirmed in the Netherlands.
Of the 501 meningococcal serogroup W isolates 
collected in England between 2010–11 and 2015–16, 
443 (88%) belonged to cc11, 52 (10%) to cc22, three (1%) 
to cc23, one (<1%) to cc174, and two (<1%) to 
cc-unassigned (both ST-9316). 187 (42%) of the 
443 English MenW:cc11 isolates from 2010–11 to 2015–16 
Figure 3: Incidence of invasive meningococcal serogroup W disease caused by the South American MenW:cc11 
strain sublineage
Incidence is for the original UK strain and the 2013 strain by epidemiological year in England and the Netherlands, 
2009–10 to 2015–16. The arrow shows the start of implementation of quadrivalent conjugate meningococcal 
vaccine (MenACWY) vaccination in the UK in 2015. cc11=sequence type-11 clonal complex.
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belonged to the 2013 strain. Of the 53 sequenced 
serogroup W strains from the Netherlands between 
2008–09 and 2015–16, 29 (55%) belonged to cc11, of 
which 26 (90%) belonged to the 2013 strain. The 
remaining serogroup W strains included 19 (36%) 
belonging to cc22, one (2%) to cc167, and four (8%) to 
cc-unassigned (three ST-5436 and one ST-12348).
In England, the South American strain sublineage 
emerged in 2009–10 (the original UK strain) and, from 
2013, an increasing number of cases belonged to the new 
2013 strain (figures 2, 3). In the Netherlands, the original 
UK strain emerged in 2012–13 and was responsible for 
three cases of meningococcal serogroup W disease; no 
cases due to the original UK strain were detected in 
subsequent years. The 2013 strain, which was first 
identified in the Netherlands in 2013–14, became 
established and is now responsible for most MenW:cc11 
cases (figures 2, 3). Within this outbreak of the 2013 
strain, we identified a distinct genetic cluster among 
16 isolates causing disease in 2015–16 (figure 2). Notably, 
the incidence of strains not belonging to cc11 remained 
stable over the study period.
Figure 4 shows the age distribution of meningococcal 
serogroup W cases belonging to the South American 
MenW:cc11 strain sublineage in the Netherlands and 
England. In England, an increase first occurred in people 
aged 25–64 in 2010–11 and in people aged 65 years and 
older in 2011–12. Subsequently, in 2012–13, cases 
increased in children and adolescents aged 10–19 years 
followed by an increase in cases among children younger 
than 5 years in 2013–14 and 2014–15.8 In the Netherlands, 
the outbreak started in 2015–16, mainly among people 
aged 65 years and older, with an increase among 
10−19 year olds from July to September, 2016 (data not 
shown). The age distribution of cases due to MenW:cc11 
in the Netherlands in 2015–16 was similar to the age 
distribution in England in 2013–14, although, in the 
Netherlands, there were more cases in people aged 
65 years and older than in England (12 [55%] of 22 patients 
in the Netherlands vs 27 [36%] of 75 patients in England).
Of the 79 patients in the Netherlands diagnosed with 
meningococcal serogroup W disease between July, 2015, 
and March, 2017, inclusive, six (8%) were aged 0−4 years 
(all aged <2 years), one (1%) was aged 5−9 years, 12 (15%) 
were aged 10−19 years, five (6%) were aged 20−24 years, 
25 (32%) were aged 25−64 years, and 30 (38%) were aged 
65 years or older. Nine patients died (11% case fatality). 
The clinical manifestation was known for 71 cases: 
32 (45%) patients had septicaemia, 14 (20%) had 
meningitis, and seven (10%) had both septicaemia and 
meningitis. The other 18 (25%) patients had atypical 
clinical manifestations, including bacteraemic 
pneumonia (12 patients), septic arthritis (four patients), 
pericarditis (one patient), and necrotising fasciitis 
(one patient15). The cases were not geographically 
clustered and none were epidemio logically related.
From 1992–93 to 2009–10, 5377 cases of meningococcal 
serogroup C disease were reported in England and 
1270 were reported in the Netherlands. Similar to the 
current serogroup W outbreak, the increase in serogroup C 
incidence in the Netherlands started several years after the 
increase in incidence in England (figure 1). Additionally, 
the incidence of serogroup C disease increased more 
gradually in England, with an annual relative increase of 
22% (95% CI 19−26) during 1994–95 to 1998–99, whereas 
in the Netherlands, a sudden increase occurred, with an 
annual relative increase of 88% (69−109) during 1999–2000 
to 2001–02. The difference in the annual relative increase 
between England and the Netherlands was significant 
(p<0·001). The age distribution of patients during the 
current serogroup W outbreak is different from that of the 
serogroup C outbreak, in which 0−4 year olds and 
10−19 year olds were the most affected age groups. 
However, the age distributions of the patients with 
serogroup C disease were similar between outbreaks in 
England and the Netherlands (figure 5).
Figure 4: Cases of invasive meningococcal serogroup W disease caused by the South American MenW:cc11 
strain sublineage
Cases are by age group and epidemiological year in England (A) and the Netherlands (B), 2009–10 to 2015–16. 
The arrow shows the start of implementation of quadrivalent conjugate meningococcal vaccine (MenACWY) 
vaccination in the UK in 2015. cc11=sequence type-11 clonal complex.
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Discussion
The rapidly evolving outbreak of meningococcal 
serogroup W disease in the Netherlands is caused by a 
MenW:cc11 outbreak strain, which emerged in England 
in 2013. We found notable similarities when comparing 
the current serogroup W outbreaks and the historical 
serogroup C outbreak between the Netherlands and 
England. In both outbreaks, the increase in incidence 
started several years later in the Netherlands than in 
England and the rate of increase was higher in the 
Netherlands than in England. Our genomic analysis 
showed that the Dutch serogroup W isolates were 
closely related to the English serogroup W isolates, with 
almost all belonging to the 2013 strain. Furthermore, 
the age distributions of patients with serogroup W 
disease due to the MenW:cc11 South American strain 
sublineage were similar between the Netherlands and 
England, although patients aged 65 years and older 
were more commonly affected in the Netherlands. The 
age distribution of patients with serogroup W disease, 
with a relatively large number of patients older than 
25 years, is not typical of meningococcal disease; for 
example, the incidence of serogroup B disease is 
highest in children younger than 5 years and 
adolescents.10 The similarities in epidemiology between 
the Dutch and English outbreaks of serogroup W and 
serogroup C disease suggest that disease trends in 
England might predict the evolution of the serogroup W 
outbreak in the Netherlands. However, since the UK 
implemented a nationwide vaccination programme 
against meningococcal serogroup W disease for 
adolescents in the summer of 2015, future trends in 
disease epidemiology in the Netherlands can no longer 
be extrapolated from the situation in England.
Other characteristics of the meningococcal serogroup 
W disease outbreak in the UK, including the high case 
fatality rate and the high proportion of patients with an 
atypical clinical manifestation,8 have also been seen in 
the Netherlands. The case fatality rate of 11% for 
serogroup W disease in the Netherlands was higher than 
the 3% reported for serogroup B disease during the past 
2 years. The proportion of patients with serogroup W 
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disease who had atypical clinical manifestations (25%) 
was also higher than the proportion of patients with 
serogroup B disease who had atypical clinical 
manifestations (3−5% in the Netherlands during the past 
2 years). In a case review of teenagers in the UK 
diagnosed with serogroup W disease between July, 2015, 
and January, 2016, seven of 15 teenagers presented 
predominantly with an acute history of gastrointestinal 
symptoms and five of these seven patients died.27 This 
clinical presentation with predominantly gastrointestinal 
symptoms is rare and seems to be associated with the 
current outbreak strain in both the UK and Chile.28 
In the Netherlands, three patients with septicaemia, 
one of whom died, presented predominantly with 
gastrointestinal symptoms.15 No geographical clustering 
or epidemiologically linked cases were found in the 
Netherlands, and in the UK, there have only been a few 
clusters.14,29
A strong argument supporting the emergency intro-
duction of the serogroup W meningococcal vaccination 
programme in the UK was the rapid acceleration of the 
spread of MenW:cc11 cases across all age groups, with a 
real possibility that disease rates could mirror the 
MenC:cc11 outbreak in the 1990s.30 For the first time in 
more than a decade, in addition to the rapidly increasing 
number of cases, serogroup W-related deaths were 
reported in infants, toddlers, and adolescents. 
Identification of the responsible MenW:cc11 strain as 
genetically related to the South American strain also 
raised concerns because of the high case fatality rate in 
Chile.28 The implementation of the serogroup W 
vaccination programme in the UK involved replacing the 
booster dose of the MenC vaccine given at 13−14 years of 
age with a MenACWY conjugate vaccine, which was 
accompanied by a catch-up campaign targeting older 
teenagers. In the Netherlands, seroepi demiological data 
also suggest that a MenC vaccine booster in adolescence 
might be needed because of waning immunity after 
infant vaccination,31 with most adolescents in the 
Netherlands no longer being protected against this 
serogroup. Nevertheless, because of continued herd 
protection, cases of serogroup C disease have so far been 
extremely rare in Dutch adolescents since the introduction 
of the vaccination programme in 2002. In the UK, 
seroepidemiological data and modelling predictions7,32 
were the basis for introducing a teenage MenC vaccine 
booster, and a pre-emptive precautionary approach was 
taken to maintain herd protection.33 The serogroup W 
outbreak provides an additional and urgent impetus for a 
comprehensive review of the potential benefit of 
meningococcal vaccination in adolescence in the 
Netherlands.
The number of cases of meningococcal serogroup W 
disease in England continued to increase in 2015–16, 
although the number is no longer doubling compared 
with previous years. School leavers (aged 17–18 years) 
were offered the MenACWY vaccine mostly through 
invitation by their general practitioners. In 2015 and 2016 
uptake has been disappointing at 38% and 30%, 
respectively, by the end of October 2016.34 Data on school 
leavers showed that, despite the low vaccination uptake, 
there have been 69% fewer cases of serogroup W disease 
in this group than was predicted by trend analysis and no 
cases have occurred among vaccinated teenagers.35 The 
UK introduced the serogroup B meningococcal (MenB) 
vaccine into the national immunisation programme in 
September, 2015, as a three-dose schedule at 2, 4, and 
12 months of age,10 which might also provide some 
protection against serogroup W disease in infants.35,36 
Uptake of the MenACWY vaccine in children immunised 
in schools was much higher than in school leavers, at 
77·2% for those born from Sept 1, 2000, to Aug 31, 2001, 
and 84·1% for those born from Sept 1, 2001, to 
Aug 31, 2002.37 It is unknown what the vaccination uptake 
would be in the Netherlands if the MenACWY vaccine 
were offered to, for example, adolescents. Vaccination 
uptake during the MenC vaccine catch-up campaign in 
2002 was high. The overall uptake was 94%,38 but coverage 
was somewhat lower at 89% in the 15−18-year age group. 
Coverage of the routine MenC vaccine at 14 months has 
been 95−96% since the start of the programme.39 We 
presume that acceptance or uptake of MenACWY 
vaccination will be similar to that of the MenC vaccine, 
because the vaccines are very similar with respect to 
immunogenicity, safety, and targeted disease.40,41
We noted some important differences in the progress of 
the outbreaks of meningococcal serogroup W disease 
between England and the Netherlands. For example, in 
England, cases of serogroup W disease appeared to 
increase more gradually over time (with cases eventually 
doubling in more recent years) than in the Netherlands, 
where the incidence increased by five times within 1 year, 
albeit with small numbers of cases. An explanation for the 
more rapid increase in the Netherlands could be that the 
MenW:cc11 cases in the Netherlands mostly belonged to 
the 2013 strain, which seems to have a greater propensity 
to spread rapidly than that of previous strains, with several 
European countries now also reporting cases of 
meningococcal disease due to this strain.14 It has been 
proposed that genetic differences defining the 2013 strain, 
such as specific virulence factor variants, might make it 
more efficient in establishing carriage and causing 
invasive disease.14 We also found a more rapid increase in 
cases of serogroup C disease in the Netherlands than in 
England. Possibly, a similar mechanism might also have 
occurred for these outbreaks, whereby a more virulent 
strain evolved in England, which might have spread to the 
Netherlands. However, the absence of sequence data for 
the historical serogroup C isolates precludes an analysis to 
investigate this possibility. Alternatively, the susceptibility 
to invasive meningococcal disease might differ between 
the populations of England and the Netherlands. However, 
there is no evidence to suggest this is the case. Additionally, 
the overall incidence of meningococcal disease has been 
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higher in the UK than in the Netherlands for a long time.42
Information from public health institutes suggests that 
the incidence of meningococcal serogroup W disease is 
increasing in several other countries in Europe, including 
Belgium, Denmark, France, Germany, Norway, Spain, 
and Sweden, albeit with small numbers of cases (personal 
communication between Dec 12, 2016, and Feb 9, 2017, 
with Bertrand S, Public Health Institute of Belgium; 
Hoffmann S, Valentiner-Branth P, Public Health Institute 
of Denmark; Barret A S, Public Health Institute of France; 
Hellenbrand W, Public Health Institute of Germany; 
Vestrheim D, Public Health Institute of Norway; and Roth 
A, Public Health Institute of Sweden).43,44 An increase was 
also reported in the incidence of serogroup W disease due 
to the South American strain sublineage in Australia in 
2015.45 Notably, during the serogroup C outbreak around 
the year 2000, serogroup C incidence did not increase in 
the Scandinavian countries and, consequently, the MenC 
vaccine is not included in the national immunisation 
programmes of these countries, except for Iceland. A 
possible explanation for the larger increase in cases of 
serogroup W disease in the Netherlands than in other 
European countries could be the close connection 
between the UK and the Netherlands in terms of the 
short distance and high levels of travel between the 
countries. Another explanation might be population 
density which, of the countries in Europe (except for 
Malta), is highest in the Netherlands.46
A potential limitation of this study is that we might 
have missed a small number of cases of meningococcal 
disease. However, both England and the Netherlands 
have robust surveillance systems for meningococcal 
disease that are based on clinical and laboratory 
notifications. It is very unlikely that clinicians are 
selectively over-reporting or under-reporting cases of 
serogroup W disease compared with other strains, 
because serogrouping is performed at national reference 
laboratories in both countries; the serogroup is, 
therefore, not known at the time of notification. It is, 
however, possible that atypical presentations are less 
likely to be investigated for meningococcal disease and, 
therefore, if a capsular group is associated with atypical 
disease in a specific age group (such as pneumonia in 
elderly people or gastrointestinal symptoms in young 
adults, for example), then there might be some bias in 
the surveillance.
We describe the emergence in the Netherlands of a 
hypervirulent MenW:cc11 strain, which has been 
associated with outbreaks of meningococcal disease in 
South America since 2003 and the UK since 2009. We 
found substantial similarities between the Netherlands 
and England during both the current outbreaks of 
meningococcal serogroup W disease and historical 
serogroup C outbreaks. Given the rapid expansion of the 
MenW:cc11 2013 strain, the high case fatality rate, and the 
availability of a safe and effective vaccine, urgent 
consideration is needed for potential public health actions, 
including vaccination, in the Netherlands and other 
countries affected by the outbreak of meningococcal 
serogroup W to prevent further cases and deaths.
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